SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): MARCH 18, 2002
EPIX MEDICAL, INC.
(Exact name of registrant as specified in its charter)
DELAWARE 000-21863 04-3030815
-------- ----------- ----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
71 ROGERS STREET
CAMBRIDGE, MASSACHUSETTS 02142
------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (617) 250-6000
--------------
ITEM 5. OTHER EVENTS.
On March 18, 2002, the Company announced that it will be presenting a
positive report of the first Phase III clinical trial data that illustrates
the potential clinical utility of magnetic resonance angiography (MRA) images
enhanced by MS-325, a blood pool contrast agent developed by the Company. The
preliminary Phase III data will be presented to Cardiologists attending the 2002
American College of Cardiology Annual Scientific Session in Atlanta on March 18,
2002.
The preliminary Phase III data will be presented in more detail, along with
Phase II data, during a presentation given by Dr. Emile R. Mohler, III entitled
"Results of a Dose-Ranging Diagnostic Trial of Magnetic Resonance Angiography
With MS-325, a Blood Pool Contrast Agent, for the Detection of Vascular
Occlusive Disease in the Aortoiliac Region." Dr. Mohler is a noted cardiologist,
MS-325 investigator and the Director of Vascular Medicine at the University of
Pennsylvania Health System.
The press release announcing the presentation of the preliminary Phase III
clinical trial results is filed as an exhibit to this Form 8-K, and is
incorporated by reference into this Item 5. The foregoing description of such
document and the clinical results contemplated therein is qualified in its
entirety by reference to such exhibit.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) Exhibits
99.1 Press Release of the Company dated March 18, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Company has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
EPIX MEDICAL, INC.
(Registrant)
Date: March 18, 2002
/s/ Michael D. Webb
-----------------------
Michael D. Webb
Chief Executive Officer
EXHIBIT INDEX
EXHIBIT NUMBER DESCRIPTION
-------------- -----------
99.1 Press Release of the Company dated March 18, 2002